Patents by Inventor Ravindra Kumar

Ravindra Kumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220090298
    Abstract: A capillary type multi-jet nozzle is provided for fabricating high throughput nanofibers by an electrospinning technique. The capillary type multi-jet nozzle includes a cap system with one or more pores and a crew system with a screw groove system. The cap system and the crew system are connected through a cap and crew system. The pores in the cap system are customized in count based on an requirement. The angle between the pores is reduced to make multiple non-interfering and non-hindering jets in less time. A Teflon gasket is used for proper tightening and sealing of the cap system and screw system. The cap system includes knurling at an outer surface for grip. The capillary type multi-jet nozzle is made of a conducting material to withstand a high voltage and is fabricated using micro-machining process.
    Type: Application
    Filed: November 11, 2019
    Publication date: March 24, 2022
    Inventors: SHIVENDU RANJAN, MAHESH KUMAR, RAVINDRA KUMAR, UPAMA TIWARI, SHIVAM ANSACH, SANDIP PATIL
  • Patent number: 11279746
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 22, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • Patent number: 11267865
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 8, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Erik M. Vogan
  • Publication number: 20220064199
    Abstract: An integrated approach for utilizing waste products of 2G bio-refineries to fractionate the lignin of high purity. The present invention also provides a method of recycling of two waste products (2-G ethanol residue as the substrate (LRBR) and fusel oil/synthetic fusel oil (SFO) as one of the solvent) of the biorefineries in a beneficial manner to fractionate the lignin of high purity. The present method of separating high purity lignin comprises fractioning extractive-free lignin rich residue with a solvent, wherein the solvent is a mixture of SFO/Fusel oil and Formic acid. An optimized ratio of waste fusel oil and formic acid gave more than >85% yields of high purity lignin.
    Type: Application
    Filed: August 25, 2021
    Publication date: March 3, 2022
    Applicants: INDIAN OIL CORPORATION LIMITED, DEPARTMENT OF BIOTECHNOLOGY
    Inventors: Alok SATLEWAL, Ruchi AGRAWAL, Ravindra KUMAR, Ravi Prakash GUPTA, Suresh Kumar PURI, Deepak SAXENA, Sankara Sri Venkata RAMAKUMAR
  • Publication number: 20220042941
    Abstract: An example heterostructure semiconductor for sensing a gas comprises a substrate made of nanosheets of a compound of a first metal, wherein the compound of the first metal is sensitive to the gas to be sensed; one or more 1-Dimensional (1D) components fabricated on a surface of the substrate, the 1D components comprising a compound of a second metal, wherein the compound of the second metal is selective to the gas to be sensed; and a 2-Dimensional (2D) layer formed on the surface of the substrate in portions excluding the 1D components, wherein the 2D layer comprises compounds of the first and second metal. Method of fabrication of the heterostructure semiconductor and a chemiresistive sensor made thereof are also disclosed.
    Type: Application
    Filed: August 10, 2021
    Publication date: February 10, 2022
    Inventors: Neha Sakhuja, Ravindra Kumar Jha, Ranajit Sai, Navakanta Bhat
  • Publication number: 20220027067
    Abstract: Methods and apparatuses for improve data clock to reduce power consumption are presented. The apparatus includes a memory configured to receive a data clock from a host via a link and to synchronize the data clock with the host. The memory includes a clock tree buffer configured to toggle based on the data clock to capture write data or to output read data and a command decoder configured to detect a data clock suspend command while the data clock is synchronized between the host and the memory. The clock tree buffer is configured to disable toggling based on the data clock in response to the command decoder detecting the data clock suspend command. the host includes a memory controller configured to provide a data clock suspend command to the memory via the link while the data clock is synchronized between the host and the memory.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Inventors: Jungwon SUH, Dexter Tamio CHUN, Michael Hawjing LO, Shyamkumar THOZIYOOR, Ravindra KUMAR
  • Publication number: 20220017600
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: February 25, 2021
    Publication date: January 20, 2022
    Applicants: Acceleron Pharma Inc., Ludwig Institute for Cancer Research Ltd.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
  • Publication number: 20220017639
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Application
    Filed: February 26, 2021
    Publication date: January 20, 2022
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Patent number: 11219666
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: January 11, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, John Knopf
  • Publication number: 20220003698
    Abstract: The present invention relates to a method based on proton NMR technique to differentiate genuine and spurious Hand-rub formulations. This method identifies and estimates all four components present in WHO-recommended Hand-rub formulations. Further, this method also identifies the presence of non-recommended/additional components present in WHO-recommended Hand-rub formulations. The method described in this invention utilizes experimental parameters and derived equations to quantify all four components in just fifteen minutes without using any organic solvents.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 6, 2022
    Inventors: Ravindra KUMAR, Sujit MONDAL, Christopher JAYARAJ, Gurpreet Singh KAPUR, Sankara Sri Venkata RAMAKUMAR
  • Patent number: 11208460
    Abstract: In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: December 28, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako
  • Patent number: 11203624
    Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides T?RII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: December 21, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani
  • Publication number: 20210388104
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: January 4, 2021
    Publication date: December 16, 2021
    Applicants: Ludwig Institute for Cancer Research Ltd., Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
  • Publication number: 20210380663
    Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIB:T?RII heteromultimers comprising an ActRIIB polypeptide and a T?MII polypeptide). In some embodiments, the disclosure provides for novel binders comprising a T?RII polypeptide and a heterologous portion. The disclosure further provides that such multispecific binders (e.g., ActRII:T?RII heteromultimer) may be used to treat various disorders or conditions.
    Type: Application
    Filed: May 2, 2019
    Publication date: December 9, 2021
    Inventors: Ravindra Kumar, Dianne S. Sako, Roselyne Castonguay, Tzu-Hsing Kuo
  • Patent number: 11193177
    Abstract: An advantageous process for pre-treating lignocellulosic biomass to hydrolysable polysaccharide enriched biomass with reduced amount of inhibitors of catalysis comprising steps of: providing a feedstock comprising cellulosic biomass; chopping of cellulosic biomass to have a cellulosic biomass feed material of uniform size; feeding of uniform sized feed material to a horizontal counter current extraction unit; removing excess of water from the feed material obtained from the extraction unit; soaking the extruded feed material obtained from the extraction unit; optionally removing excess of water from the feed material obtained after acid soaking; steam pre-treating the feed material obtained after removing excess of water from the acid soaked feed material; neutralizing the slurry obtained from the steam pre-treating; and optionally saccharifying the neutralized slurry.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: December 7, 2021
    Assignees: Indian Oil Corporation Limited, Department of Biotechnology
    Inventors: Ravindra Kumar, Surbhi Semwal, Alok Satlewal, Ravi Prakash Gupta, Suresh Kumar Puri, Sankara Sri Venkata Ramakumar
  • Publication number: 20210362370
    Abstract: A thin-walled honeycomb body (100) having a plurality of repeating cell structures (110) formed of intersecting porous thick walls (112V, 112H) and thin walls (114V, 114H). Each repeating cell structure (110) is bounded on its periphery by the thick walls (112V, 122H) of a first transverse thickness (Tk) and the thin walls (114V, 114H) have a second transverse thickness (Tt) that subdivides each repeating cell structure (110) into between 7 and 36 individual cells (108). In the thin-walled honeycomb body (100), the first transverse thickness (Tk) of the thick walls (112V, 112H) is less than or equal to 0.127 mm (0.005 inch) and the second transverse thickness (Tt) of the thin walls (114V, 114H) is less than or equal to 0.0635 mm (0.0025 inch), and Tk>Tt. Honeycomb extrusion dies and methods of manufacturing the thin-walled honeycomb body (100) having thick walls (112V, 112H) and thin walls (114V, 114H) are provided.
    Type: Application
    Filed: December 16, 2018
    Publication date: November 25, 2021
    Inventors: Ravindra Kumar Akarapu, Amit Halder, Priyank Paras Jain, Weidong Li
  • Publication number: 20210363502
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
    Type: Application
    Filed: December 28, 2020
    Publication date: November 25, 2021
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay
  • Patent number: 11175836
    Abstract: Methods and apparatuses for improve data clock to reduce power consumption are presented. The apparatus includes a memory configured to receive a data clock from a host via a link and to synchronize the data clock with the host. The memory includes a clock tree buffer configured to toggle based on the data clock to capture write data or to output read data and a command decoder configured to detect a data clock suspend command while the data clock is synchronized between the host and the memory. The clock tree buffer is configured to disable toggling based on the data clock in response to the command decoder detecting the data clock suspend command. the host includes a memory controller configured to provide a data clock suspend command to the memory via the link while the data clock is synchronized between the host and the memory.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: November 16, 2021
    Assignee: QUALCOMM Incorporated
    Inventors: Jungwon Suh, Dexter Tamio Chun, Michael Hawjing Lo, Shyamkumar Thoziyoor, Ravindra Kumar
  • Patent number: 11168311
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: November 9, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Patent number: 11162085
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: November 2, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar